Aventura Private Wealth LLC Buys New Shares in Boston Scientific Corporation $BSX

Aventura Private Wealth LLC bought a new position in Boston Scientific Corporation (NYSE:BSX) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 12,673 shares of the medical equipment provider’s stock, valued at approximately $1,208,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Brighton Jones LLC lifted its holdings in shares of Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after buying an additional 226 shares in the last quarter. Wealthspire Advisors LLC grew its stake in Boston Scientific by 11.6% during the second quarter. Wealthspire Advisors LLC now owns 6,926 shares of the medical equipment provider’s stock valued at $744,000 after acquiring an additional 719 shares in the last quarter. Traub Capital Management LLC bought a new stake in Boston Scientific in the 2nd quarter valued at $43,000. ABN AMRO Bank N.V. bought a new stake in Boston Scientific in the 2nd quarter valued at $5,264,000. Finally, Personal CFO Solutions LLC lifted its stake in Boston Scientific by 28.8% in the 2nd quarter. Personal CFO Solutions LLC now owns 2,793 shares of the medical equipment provider’s stock worth $300,000 after purchasing an additional 624 shares in the last quarter. 89.07% of the stock is owned by institutional investors.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Needham/analyst support — Needham & Company maintained a Buy rating and $97 price target, arguing the financial fallout from the Accolade pacemaker recalls is limited and supports a continued Buy stance. Boston Scientific: Limited Financial Fallout From Pacemaker Recalls Supports Continued Buy Rating
• Neutral Sentiment: Stifel trims target but keeps Buy — Stifel cut its price target from $110 to $90 while retaining a Buy rating, reducing upside expectations even as the firm remains constructive. Benzinga: Stifel Nicolaus Price Target
• Neutral Sentiment: Other firms lower expectations — Truist and UBS have lowered price targets/expectations (Truist to $92), signaling more cautious analyst views on near-term growth despite mixed analyst conviction. Truist Lowers Boston Scientific Price Target to $92
• Negative Sentiment: Multiple securities class-action alerts — Several law firms have filed or are soliciting lead plaintiffs for securities fraud suits tied to disclosures covering July 2025–Feb 2026; reminders and deadlines (May 4, 2026) are fueling legal uncertainty and potential future liability. Boston Scientific Corporation (BSX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Negative Sentiment: NYT report alleges long-standing battery issues — The New York Times reports Boston Scientific was aware of pacemaker battery problems for years, a story that raises reputational and regulatory risk beyond the company’s stated scope. Boston Scientific Knew of Pacemaker Battery Problems for Years
• Negative Sentiment: Recall expanded — Market chatter notes Boston Scientific amended its Accolade pacemaker recall, increasing the affected population to ~1.6 million devices, which raises potential remediation costs and investor concern. Market Chatter: Boston Scientific Amends Recall of Accolade Pacemakers, Affected Population Now 1.6 Million
• Negative Sentiment: High-profile criticism — Jim Cramer publicly criticized BSX’s recent performance and competitive pressures, a sentiment that can influence retail flows and short-term sentiment. Jim Cramer on Boston Scientific: “This Stock Was One of the Greatest Performers, It’s Not Anymore”

Insider Buying and Selling at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. This represents a 10.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Price Performance

NYSE:BSX opened at $69.54 on Friday. The stock has a market capitalization of $103.34 billion, a PE ratio of 35.84, a price-to-earnings-growth ratio of 0.98 and a beta of 0.69. Boston Scientific Corporation has a 52 week low of $67.56 and a 52 week high of $109.50. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. The stock’s 50-day moving average price is $79.74 and its 200-day moving average price is $92.15.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The firm had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same quarter last year, the firm posted $0.70 EPS. The business’s revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, equities analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on BSX. Wall Street Zen upgraded Boston Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, March 14th. JPMorgan Chase & Co. decreased their target price on Boston Scientific from $135.00 to $100.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Jefferies Financial Group reissued a “buy” rating on shares of Boston Scientific in a research note on Monday. Mizuho lowered their target price on Boston Scientific from $140.00 to $115.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. Finally, Citigroup cut their target price on shares of Boston Scientific from $102.00 to $94.00 and set a “buy” rating for the company in a report on Wednesday, March 11th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $106.27.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.